Exelixis (EXEL) returns

Biotechnology · NASDAQ · Health Care

$69.39 +4.82% Close Oct 30, 2026 Live

Exelixis returns over 10 years

$1,000 invested in Exelixis ten years ago was worth $6,378 at the close on October 30, 2026, with dividends reinvested: an average return of 20.4% a year. The same $1,000 in the S&P 500 (SPY) became $4,166.

EXEL, $10,000 investedS&P 500 (SPY)
$20,000$40,000$60,000
20172019202120232025

Total return by period

With dividends reinvested, to the close on Oct 30, 2026. A year means 365 days.
PeriodTotal returnA year, on average$1,000 becameS&P 500 (SPY)
1 month +18.8% — $1,188 -0.9%
3 months +24.0% — $1,240 +2.1%
Year to date +58.3% — $1,583 +11.7%
1 year +78.2% — $1,782 +12.4%
3 years +242.8% +50.8% $3,428 +88.5%
5 years +222.6% +26.4% $3,226 +76.0%
10 years +537.8% +20.4% $6,378 +316.6%

Exelixis return by calendar year

YearEXELS&P 500 (SPY)Difference
2026 to date +58.3% +11.7% +46.6%
2025 +31.6% +17.7% +13.9%
2024 +38.8% +24.9% +13.9%
2023 +49.6% +26.2% +23.4%
2022 -12.3% -18.2% +5.9%
2021 -8.9% +28.7% -37.7%
2020 +13.9% +18.4% -4.5%
2019 -10.4% +31.2% -41.6%
2018 -35.3% -4.6% -30.7%
2017 +103.9% +21.7% +82.2%
2016 +164.4% +12.0% +152.4%

Past returns do not predict future returns. Returns are computed from our daily closes, adjusted for splits and with dividends reinvested on their ex-dates; taxes and trading costs are left out.

See also: EXEL financials · EXEL valuation

No forecast, no recommendation. This page describes Exelixis from published data; it is not advice to buy, sell or hold any security.

Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.